文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

哪些重症COVID-19患者可能从高剂量地塞米松中获益?COVIDICUS随机临床试验的贝叶斯事后重分析

Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial.
PubMed 文献 · Ann Intensive Care · 2023-08-27
一句话结论贝叶斯事后分析提示,高剂量地塞米松可能对年龄<70岁、症状出现<7天的重症急性呼吸衰竭患者有获益,合用瑞德西韦可能有利于获益。

COVIDICUS试验中未发现高剂量地塞米松(DXM20)较标准治疗6 mg地塞米松(DXMSoC)有额外获益。本研究对473例患者进行事后探索性贝叶斯分析,结局为60天死亡率,以Cox模型估计的风险比(HR)衡量疗效。总体而言,DXM20较DXMSoC获得超过微小获益的后验概率为29.0%,潜在危害的后验概率为51.1%。亚组交互分析显示,年龄<70岁者获益概率为86.5%(≥70岁为22%),症状出现<7天者获益概率为99.9%(≥7天为<0.1%),使用瑞德西韦者获益概率为90.1%(未使用者为19.1%)。作者认为高剂量地塞米松可能使年龄<70岁且症状出现<7天即发生严重急性呼吸衰竭的患者获益,瑞德西韦的使用也可能有利于DXM20的获益,需进一步分析证实。

要点

  • 总体人群中,DXM20较DXMSoC获得超过微小获益(HR<0.95)的后验概率为29.0%,潜在危害(HR>1.05)的后验概率为51.1%。
  • 年龄<70岁患者DXM20获益概率为86.5%,≥70岁患者为22%,年龄亚组交互概率Pr Interact为84%。
  • 症状出现<7天患者DXM20获益概率为99.9%,≥7天患者为<0.1%,时间亚组交互概率Pr Interact为99%。
  • 使用瑞德西韦患者DXM20获益概率为90.1%,未使用者为19.1%,瑞德西韦亚组交互概率Pr Interact为91%。
  • 作者认为,与标准治疗地塞米松相比,高剂量地塞米松可能使年龄<70岁、症状出现<7天即发生严重急性呼吸衰竭的患者获益,瑞德西韦的使用也可能有利于DXM20的获益,需进一步分析证实。

适用人群与场景

  • COVIDICUS试验中接受DXMSoC或DXM20治疗的473例重症SARS-CoV-2感染伴急性呼吸衰竭患者。
  • 事后探索性贝叶斯分析,按年龄(<70岁 vs ≥70岁)、症状出现至急性呼吸衰竭时间(<7天 vs ≥7天)、是否使用瑞德西韦进行亚组分析。

诊断标准与关键阈值

  • 超过微小获益定义为HR<0.95,潜在危害定义为HR>1.05。
  • 亚组交互概率Pr Interact用于量化各亚组间死亡HR差异达20%的概率。

处置流程与药物剂量

  • 干预为高剂量地塞米松(DXM20)对比标准治疗6 mg地塞米松(DXMSoC);原文未给出DXM20的具体剂量、给药途径和频次。

研究设计与关键结果

  • 研究类型:COVIDICUS随机临床试验的事后探索性贝叶斯分析,纳入473例接受DXMSoC或DXM20的患者,结局为60天死亡率,以Cox模型估计HR。
  • 总体人群中,DXM20较DXMSoC获得超过微小获益(HR<0.95)的后验概率为29.0%,潜在危害(HR>1.05)的后验概率为51.1%。
  • 年龄亚组:年龄<70岁患者DXM20获益概率为86.5%,≥70岁患者为22%,Pr Interact为84%。
  • 症状出现时间亚组:<7天患者DXM20获益概率为99.9%,≥7天患者为<0.1%,Pr Interact为99%。
  • 瑞德西韦亚组:使用瑞德西韦患者DXM20获益概率为90.1%,未使用者为19.1%,Pr Interact为91%。
  • 主分析使用以HR=1.00为中心的无信息先验;敏感性分析使用基于无效(HR=1.00)或获益(HR=0.95)效应的怀疑先验和热情先验。

证据类型、等级与局限

  • 证据类型:随机对照试验的事后探索性贝叶斯重分析(post hoc exploratory Bayesian analysis)。
  • 局限:为事后探索性分析;作者指出需进一步分析证实这些发现(Further analysis is needed to confirm these findings)。

对床旁实践的改变

  • 作者认为,与标准治疗地塞米松相比,高剂量地塞米松可能使年龄<70岁、症状出现<7天即发生严重急性呼吸衰竭的重症COVID-19患者获益。
  • 作者认为,瑞德西韦的使用也可能有利于高剂量地塞米松的获益。
  • 作者指出需进一步分析证实这些发现。

指南或共识出处

  • COVIDICUS随机临床试验(NCT04344730,注册日期2020年4月14日;EudraCT:2020-001457-43)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure (ARF) are controversial, with two large triple-blind RCTs reaching very important difference in the effect-size. In the COVIDICUS trial, no evidence of additional benefit of high-dose dexamethasone (DXM20) was found. We aimed to explore whether some specific patient phenotypes could benefit from DXM20 compared to the standard of care 6 mg dose of DXM (DXMSoC).

METHODS: We performed a post hoc exploratory Bayesian analysis of 473 patients who received either DXMSoc or DXM20 in the COVIDICUS trial. The outcome was the 60 day mortality rate of DXM20 over DXMSoC, with treatment effect measured on the hazard ratio (HR) estimated from Cox model. Bayesian analyses allowed to compute the posterior probability of a more than trivial benefit (HR < 0.95), and that of a potential harm (HR > 1.05). Bayesian measures of interaction then quantified the probability of interaction (Pr Interact) that the HR of death differed across the subsets by 20%. Primary analyses used noninformative priors, centred on HR = 1.00. Sensitivity analyses used sceptical and enthusiastic priors, based on null (HR = 1.00) or benefit (HR = 0.95) effects.

RESULTS: Overall, the posterior probability of a more than trivial benefit and potential harm was 29.0 and 51.1%, respectively. There was some evidence of treatment by subset interaction (i) according to age (Pr Interact, 84%), with a 86.5% probability of benefit in patients aged below 70 compared to 22% in those aged above 70; (ii) according to the time since symptoms onset (Pr Interact, 99%), with a 99.9% probability of a more than trivial benefit when lower than 7 days compared to a < 0.1% probability when delayed by 7 days or more; and (iii) according to use of remdesivir (Pr Interact, 91%), with a 90.1% probability of benefit in patients receiving remdesivir compared to 19.1% in those who did not.

CONCLUSIONS: In this exploratory post hoc Bayesian analysis, compared with standard-of-care DXM, high-dose DXM may benefit patients aged less than 70 years with severe ARF that occurred less than 7 days after symptoms onset. The use of remdesivir may also favour the benefit of DXM20. Further analysis is needed to confirm these findings.

TRIAL REGISTRATION: NCT04344730, date of registration April 14, 2020 ( https://clinicaltrials.gov/ct2/show/NCT04344730?term=NCT04344730&draw=2&rank=1 ); EudraCT: 2020-001457-43 ( https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001457-43 ).

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Chevret S, Bouadma L, Dupuis C, et al. Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial. Ann Intensive Care. 2023. PMID: 37634234. doi:10.1186/s13613-023-01168-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。